Blueprint Medicines (NASDAQ: BPMC) reported Q3 EPS of ($0.89), $0.07 better than the analyst estimate of ($0.96). Revenue for the quarter came in at $128.18 million versus the consensus estimate of $127.56 million.

GUIDANCE:

Blueprint Medicines sees FY2024 revenue of $475-480 million, versus the consensus of $497.3 million.

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.